Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38263486)

  • 1. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
    Fadul CE; Thakur A; Kim J; Kassay-McAllister J; Schalk D; Lopes MB; Donahue J; Purow B; Dillon P; Le T; Schiff D; Liu Q; Lum LG
    J Neurooncol; 2024 Jan; 166(2):321-330. PubMed ID: 38263486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients.
    Lum LG; Thakur A; Choi M; Deol A; Kondadasula V; Schalk D; Fields K; Dufrense M; Philip P; Dyson G; Aon HD; Shields AF
    Oncoimmunology; 2020 Jun; 9(1):1773201. PubMed ID: 32939319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiotherapy Plus Temozolomide With or Without Nimotuzumab Against the Newly Diagnosed EGFR-Positive Glioblastoma: A Retrospective Cohort Study.
    She L; Gong X; Su L; Liu C
    Oncologist; 2023 Jan; 28(1):e45-e53. PubMed ID: 36181764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.
    Feldheim J; Kessler AF; Feldheim JJ; Schulz E; Wend D; Lazaridis L; Kleinschnitz C; Glas M; Ernestus RI; Brandner S; Monoranu CM; Löhr M; Hagemann C
    Int J Mol Sci; 2022 May; 23(9):. PubMed ID: 35563629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
    Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
    J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial.
    Omuro A; Brandes AA; Carpentier AF; Idbaih A; Reardon DA; Cloughesy T; Sumrall A; Baehring J; van den Bent M; Bähr O; Lombardi G; Mulholland P; Tabatabai G; Lassen U; Sepulveda JM; Khasraw M; Vauleon E; Muragaki Y; Di Giacomo AM; Butowski N; Roth P; Qian X; Fu AZ; Liu Y; Potter V; Chalamandaris AG; Tatsuoka K; Lim M; Weller M
    Neuro Oncol; 2023 Jan; 25(1):123-134. PubMed ID: 35419607
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 20(S)-ginsenoside-Rg3 reverses temozolomide resistance and restrains epithelial-mesenchymal transition progression in glioblastoma.
    Chen Z; Wei X; Shen L; Zhu H; Zheng X
    Cancer Sci; 2019 Jan; 110(1):389-400. PubMed ID: 30431207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft models.
    Cen L; Carlson BL; Pokorny JL; Mladek AC; Grogan PT; Schroeder MA; Decker PA; Anderson SK; Giannini C; Wu W; Ballman KV; Kitange GJ; Sarkaria JN
    Neuro Oncol; 2013 Jun; 15(6):735-46. PubMed ID: 23479134
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of the E2F1-RAD51AP1 axis as a key factor in MGMT-methylated GBM TMZ resistance.
    Zhou J; Tong F; Zhao J; Cui X; Wang Y; Wang G; Kang C; Liu X; Wang Q
    Cancer Biol Med; 2023 Jun; 20(5):385-400. PubMed ID: 37283490
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of lomeguatrib-temozolomide combination on MGMT promoter methylation and expression in primary glioblastoma tumor cells.
    Taspinar M; Ilgaz S; Ozdemir M; Ozkan T; Oztuna D; Canpinar H; Rey JA; Sunguroğlu A; Castresana JS; Ugur HC
    Tumour Biol; 2013 Jun; 34(3):1935-47. PubMed ID: 23519841
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M
    Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow response as a potential biomarker of outcomes in glioblastoma patients.
    Vaios EJ; Nahed BV; Muzikansky A; Fathi AT; Dietrich J
    J Neurosurg; 2017 Jul; 127(1):132-138. PubMed ID: 27739940
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiosensitizing effects of temozolomide observed in vivo only in a subset of O6-methylguanine-DNA methyltransferase methylated glioblastoma multiforme xenografts.
    Carlson BL; Grogan PT; Mladek AC; Schroeder MA; Kitange GJ; Decker PA; Giannini C; Wu W; Ballman KA; James CD; Sarkaria JN
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):212-9. PubMed ID: 19695438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Treating Fields (TTFields) increase the effectiveness of temozolomide and lomustine in glioblastoma cell lines.
    Fishman H; Monin R; Dor-On E; Kinzel A; Haber A; Giladi M; Weinberg U; Palti Y
    J Neurooncol; 2023 May; 163(1):83-94. PubMed ID: 37131108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential bortezomib and temozolomide treatment promotes immunological responses in glioblastoma patients with positive clinical outcomes: A phase 1B study.
    Rahman MA; Brekke J; Arnesen V; Hannisdal MH; Navarro AG; Waha A; Herfindal L; Rygh CB; Bratland E; Brandal P; Haasz J; Oltedal L; Miletic H; Lundervold A; Lie SA; Goplen D; Chekenya M
    Immun Inflamm Dis; 2020 Sep; 8(3):342-359. PubMed ID: 32578964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adoptive cell therapy for high grade gliomas using simultaneous temozolomide and intracranial mgmt-modified γδ t cells following standard post-resection chemotherapy and radiotherapy: current strategy and future directions.
    Nabors LB; Lamb LS; Goswami T; Rochlin K; Youngblood SL
    Front Immunol; 2024; 15():1299044. PubMed ID: 38384458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NMDA receptor signaling induces the chemoresistance of temozolomide via upregulation of MGMT expression in glioblastoma cells.
    Tsuji S; Nakamura S; Shoda K; Yamada T; Shimazawa M; Nakayama N; Iwama T; Hara H
    J Neurooncol; 2022 Nov; 160(2):375-388. PubMed ID: 36308592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting and killing of glioblastoma with activated T cells armed with bispecific antibodies.
    Zitron IM; Thakur A; Norkina O; Barger GR; Lum LG; Mittal S
    BMC Cancer; 2013 Feb; 13():83. PubMed ID: 23433400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 1 trial of ralimetinib (LY2228820) with radiotherapy plus concomitant temozolomide in the treatment of newly diagnosed glioblastoma.
    Biau J; Thivat E; Chautard E; Stefan D; Boone M; Chauffert B; Bourgne C; Richard D; Molnar I; Levesque S; Bellini R; Kwiatkowski F; Karayan-Tapon L; Verrelle P; Godfraind C; Durando X
    Radiother Oncol; 2021 Jan; 154():227-234. PubMed ID: 32976869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.